...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Auris, nasus, larynx >p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma.
【24h】

p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma.

机译：多西他赛同时放化疗中p53在头颈部鳞状细胞癌中的表达。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The current study aimed to evaluate the significance of an immunohistochemical assessment of tumor suppressor p53 as a prognostic marker in head and neck squamous cell carcinoma (HNSCC) patients treated with docetaxel and radiotherapy. METHODS: The expression of tumor suppressor p53 and its phosphorylated form at the Ser392 residue was retrospectively evaluated by immunohistochemistry in 51 Stage T1-3N0-2M0 (except T1N0 glottis) HNSCC patients who were treated with 10mg/m(2)/week docetaxel four to six times and received concurrent chemoradiotherapy. RESULTS: Kaplan-Meier univariate analysis revealed that no difference in rates for overall and disease-free survival (DFS) between patients with p53-positive and -negative tumors (p=0.786 and p=0.924, respectively). The prognostic significance of phosphorylated p53 at the Ser392 residue was neither observed. CONCLUSIONS: An immunohistochemical assessment of the expression of p53 and its phosphorylated form might not be of clinical use in defining subgroups of patients with poor prognosis.
机译：背景：目前的研究旨在评估免疫抑制剂的免疫组织化学评估p53作为多西他赛和放疗治疗的头颈部鳞状细胞癌（HNSCC）患者的预后指标。方法：采用免疫组织化学方法回顾性分析了51例T1-3N0-2M0（声门T1N0除外）HNSCC患者中10mg / m（2）/周多西他赛四期治疗的肿瘤抑制因子p53及其磷酸化形式在Ser392残基的表达。至六次并接受同步放化疗。结果：Kaplan-Meier单变量分析显示，p53阳性和阴性肿瘤患者的总生存率和无病生存率（DFS）均无差异（分别为p = 0.786和p = 0.924）。没有观察到在Ser392残基上磷酸化的p53的预后意义。结论：免疫组织化学评估p53及其磷酸化形式的表达可能不适用于定义预后不良的亚组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号